apatinib + camrelizumab + docetaxel + S-1

apatinib + camrelizumab + docetaxel + S-1 is a multi-drug combination regimen being investigated for the first-line treatment of metastatic gastric adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma. This regimen integrates apatinib, a small molecule tyrosine kinase inhibitor that selectively targets vascular endothelial growth factor receptor 2 (VEGFR-2) to inhibit tumor angiogenesis, with camrelizumab, a humanized monoclonal antibody that inhibits the programmed cell death protein 1 (PD-1) checkpoint to enhance anti-tumor immunity. These targeted agents are administered alongside a chemotherapy backbone consisting of docetaxel, a taxane that disrupts microtubule function, and S-1, an oral fluoropyrimidine combination. The regimen is currently being evaluated in clinical trials, such as the HCCSC G05 trial led by investigator Zhou Fuxiang, to determine if the integration of anti-angiogenic therapy and immunotherapy with standard chemotherapy improves clinical outcomes in advanced gastric cancers.

Other names

Apatinib plus Camrelizumab combined with Docetaxel and S1